Abstract
This article describes basic epidemiologic and clinical features of HIV disease in infants, children, and adolescents and explores controversies about pediatric research in the specific context of AIDS. Because many potentially therapeutic agents will initially be available only through clinical trials, it is essential that pediatric populations have access to such trials yet not be exposed to undue risks. Distinguishing clearly between risks posed by research interventions versus those associated with attempts to provide treatment may guide the resolution of apparent ethical dilemmas. Special attention must also be given to concerns raised by trials that involve placebo administratcon, perinatal interventions, enrollment of foster children, and consent by adolescents without parental notification .
Get full access to this article
View all access options for this article.
